KPTI News and Press, Karyopharm Therapeutics Inc. From 01/08/24

2024-01-08 12:35:53 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Karyopharm reports encouraging data for endometrial cancer drug candidate Karyopharm Therapeutics GAAP EPS of -$0.30 misses by...

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives PR Newswire – Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, En...

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announc...

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1) PR Newswire Bioma...

2023-11-29 18:48:21 ET Summary Selinexor has received three approvals but has faced disappointing sales due to competition and toxicity. Nevertheless, an already established global commercial infrastructure will support the launch of additional indications. Selinexor is being eval...

2023-11-06 10:12:23 ET More on Karyopharm Therapeutics Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0...

2023-11-02 15:30:24 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q3 2023 Earnings Call Nov 02, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q3 2023 Earnings C...

2023-11-02 14:25:25 ET Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call November 2, 2023, 08:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chi...

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH) PR Newswire Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass. , Nov. 2, 2023 /PRNewswire...

2023-11-02 07:33:14 ET More on Karyopharm Therapeutics Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away Karyopharm Therapeutics Q3 2023 Earnings Preview Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myelo...